Concordance Between ctDNA Assay and FoundationOne

Summary

Foundation Medicine Inc. (FMI) is interested in studying the concordance of genomic alterations between primary and/or metastatic surgical biopsies, and circulating tumor DNA (ctDNA) within different solid tumor types and has been developing an assay in order to do so.

Conditions

• Circulating Tumor DNA
• Cancer
• Neoplasms
• Genomic Testing
• Genomic Alterations

Sponsors & Collaborators

• Johns Hopkins University

  collaborator OTHER

• Oncology Consultants

  collaborator UNKNOWN

• Comprehensive Blood and Cancer Center

  collaborator OTHER

• Illinois CancerCare

  collaborator OTHER

• Sanford Health

  collaborator OTHER

• Eastchester Center for Cancer Care

  collaborator OTHER

• Rutgers Cancer Institute of New Jersey

  collaborator OTHER

• Cone Health

  collaborator OTHER

• Nebraska Cancer Specialists

  collaborator UNKNOWN

• University of California, Davis

  collaborator OTHER

• University of Chicago

  collaborator OTHER

• Northeast Georgia Medical Center

  collaborator UNKNOWN

• Hematology Oncology Associates of Fredericksburg

  collaborator UNKNOWN

• Memorial Sloan Kettering Cancer Center

  collaborator OTHER

• Oncology Hematology Care, Inc

  collaborator UNKNOWN

• Montefiore Medical Center

  collaborator OTHER

• Quincy Medical Group

  collaborator OTHER

• Prisma Health-Upstate

  collaborator OTHER

• Mary Crowley Cancer Research Center

  collaborator UNKNOWN

• Texas Health

  collaborator UNKNOWN

• University of California, San Diego

  collaborator OTHER

• Avera Cancer Institute

  collaborator UNKNOWN

• Foundation Medicine

  lead INDUSTRY

Principal Investigators

• Phil Stephens, PhD · Foundation Medicine

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2014-11-30

Primary Completion

2017-12-31

Completion

2017-12-31

Countries

• United States

Study Locations